Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-40411813 in Focal Onset Seizures
NCT04836559Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in focal onset seizure comparing JNJ-40411813 Arm with Placebo Arm (2 arms). Primary endpoint: Time to Baseline Monthly Seizure Count at 12 weeks. Started May 2021; status: completed.
02
Drugs
adx-71149
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT04836559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04836559.